Assay validation for vilanterol and its metabolites in human urine with application for doping control analysis.
Sign Up to like & getrecommendations! Published in 2022 at "Drug testing and analysis"
DOI: 10.1002/dta.3433
Abstract: A bioanalytical method for detecting the ultra-long-acting beta2 -agonist (U-LABA), inhaled vilanterol and its metabolites, GSK932009 and GW630200, in urine was developed to potentially monitor permitted therapeutic versus prohibited supratherapeutic use in sport. The World… read more here.
Keywords: vilanterol; gsk932009 gw630200; repeat dosing; vilanterol metabolites ... See more keywords
A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD.
Sign Up to like & getrecommendations! Published in 2017 at "Respiratory medicine"
DOI: 10.1016/j.rmed.2016.12.001
Abstract: BACKGROUND The contribution of fluticasone furoate (FF) on lung function in the FF/vilanterol (VI) 100/25 μg combination has been demonstrated numerically, but not statistically. METHODS This multicentre, randomised, double-blind, controlled trial (GlaxoSmithKline study number 200820; clinicaltrials.gov… read more here.
Keywords: contribution; vilanterol; fluticasone furoate; lung function ... See more keywords
Fluticasone furoate plus vilanterol in patients with moderate persistent asthma: a cost-utility analysis
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Asthma"
DOI: 10.1080/02770903.2022.2051547
Abstract: Abstract Background In recent years, the combination of fluticasone furoate and vilanterol (FF/VI) has emerged as an alternative therapy, since it is administered every 24 h, in contrast to other ICS/LABAs such as fluticasone propionate plus… read more here.
Keywords: fluticasone furoate; cost; vilanterol; persistent asthma ... See more keywords